Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma

En-CPhI.CNOctober 21, 2019

Tag: Innovent , Pemigatinib , cholangiocarcinoma , iCCA

PharmaSources Customer Service